Publications in collaboration with researchers from Harvard Medical School (22)

2024

  1. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Journal of the American Heart Association, Vol. 13, Núm. 15, pp. e035993

  2. Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 10, pp. 725-734

  3. Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial

    Circulation: Cardiovascular Interventions, Vol. 17, Núm. 6, pp. 457-473

  4. Ischemia Severity, Coronary Artery Disease Extent, and Exercise Capacity in ISCHEMIA

    Circulation, Vol. 150, Núm. 2, pp. 165-167

  5. REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNARelated Dilated Cardiomyopathy

    Circulation: Heart Failure, Vol. 17, Núm. 7, pp. e011548

2022

  1. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

    Circulation, Vol. 146, Núm. 16, pp. 1196-1206

  2. Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROC-DRT registry

    Clinical Research in Cardiology, Vol. 111, Núm. 11, pp. 1276-1285

  3. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

    The Lancet Diabetes and Endocrinology, Vol. 10, Núm. 1, pp. 35-45

  4. Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies

    European heart journal, Vol. 43, Núm. 23, pp. 2237-2246

  5. One-year cardiovascular outcomes after coronavirus disease 2019: The cardiovascular COVID-19 registry

    PLoS ONE, Vol. 17, Núm. 12 December

  6. Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial

    Journal of the American College of Cardiology, Vol. 79, Núm. 7, pp. 651-661

  7. The Role of Fatty Acid-Binding Protein 4 in the Characterization of Atrial Fibrillation and the Prediction of Outcomes after Catheter Ablation

    International Journal of Molecular Sciences, Vol. 23, Núm. 19

2021

  1. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

    New England Journal of Medicine, Vol. 384, Núm. 2, pp. 105-116

2020

  1. Initial invasive or conservative strategy for stable coronary disease

    New England Journal of Medicine, Vol. 382, Núm. 15, pp. 1395-1407

2019

  1. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients with Atrial Fibrillation: A Report from the GARFIELD-AF Registry

    JAMA Cardiology, Vol. 4, Núm. 6, pp. 526-548

  2. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  3. Management and 1-year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: Results from the prospective garfield-af registry

    Journal of the American Heart Association, Vol. 8, Núm. 3

2018

  1. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation

    PLoS ONE, Vol. 13, Núm. 1

2017

  1. Impact of gender on event rates at 1-year in patients with newly diagnosed non-valvular atrial fibrillation: Contemporary perspective from the GARFIELD-AF registry

    BMJ Open, Vol. 7, Núm. 3

  2. Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: Insights from the five-year follow-up of the EXAMINATION trial

    EuroIntervention, Vol. 13, Núm. 5, pp. e557-e563